Related Experiment Videos
Hematocrit levels and associated Medicare expenditures.
1University of Minnesota, Hennepin County Medical Center, Minneapolis, USA. acollins@nephrology.org
Summary
Maintaining a hematocrit of 33% to 36% in hemodialysis patients is linked to lower Medicare expenditures. This study found higher costs for patients with hematocrits below 30%.
Area of Science:
- Nephrology
- Health Economics
Background:
- Clinical guidelines recommend a target hematocrit of 33% to <36% for hemodialysis patients.
- Previous research indicates lower mortality and hospitalization risks at this hematocrit range.
Purpose of the Study:
- To examine the association between hematocrit levels and Medicare expenditures in hemodialysis patients.
- To determine if specific hematocrit ranges correlate with significant cost differences.
Main Methods:
- Analysis of incident Medicare hemodialysis patients from 1991-1995.
- Assessment of hematocrit values during a 6-month entry period.
- Evaluation of Medicare Part A and Part B per-member-per-month expenditures during a follow-up period, controlling for patient characteristics and disease severity.
Main Results:
- Hematocrit levels of 33% to <36% and ≥36% were associated with lower Medicare expenditures.
- Patients with hematocrits <30% incurred significantly higher Medicare costs compared to those with 30% to <33%.
- Expenditures were 6.0% and 8.2% lower for hematocrit ranges of 33% to <36% and ≥36%, respectively.
Conclusions:
- Achieving target hematocrit levels in hemodialysis patients may lead to substantial Medicare savings.
- While associations suggest cost-effectiveness, causality cannot be definitively established from this observational study.